Commercial poultry production is facing many health challenges, including respiratory ones. As a consequence, mitigation or reduction of virus circulation in between houses or farms is of paramount importance to keep the respiratory tract healthy and be able to reach one’s production targets.
Besides biosecurity, there is a need to get access to vaccines with the best features in terms of protection, but also prevention against the uncontrolled circulation of avian paramyxovirus type 1, also known as Newcastle disease virus in its pathogenic (‘velogenic’) form.
Vectormune ND is an innovative vector vaccine which elicits an early, broad and long-lasting immunity; vaccinated chickens shed significantly less virus than unvaccinated ones.
A recent publication* about Vectormune ND provided the additional asset of significantly reducing the likelihood of virus transmission among birds. Indeed, a velogenic Newcastle disease virus was provided with a reproduction ratio (R0) figure of 3.20, which basically means that 10 infected chickens are able to transmit the disease to 32 new birds, hence explaining the spreading capacity of this disease to neighbouring houses. The outcome will be increased losses, including high mortality rate in case of velogenic strains. On the contrary, in Vectormune ND-vaccinated broilers, this R0 dropped to 0.82, which means that vaccinated flocks will significantly reduce and slow down the spread of the virus. In addition, they will survive thanks to strong protection.
This publication helps us to understand that the innovative vector vaccine controls and prevents Newcastle disease outbreaks despite a different genotype between challenge strain and vaccine insert.
Figure – Kinetics of velogenic Newcastle disease virus shedding in vaccinated and unvaccinated birds after direct infection (seeder subgroups) or contact infection (contact subgroups). Seeder subgroups were challenged with 5.0 log 10 ELD 50 of velogenic Newcastle disease virus intra-nasally. Contacts were co-mingled with seeders from 8 hours post-challenge. Oro-nasal swabs and cloacal swabs were collected daily for 14 days post-challenge; velogenic Newcastle disease virus amount was quantified by RT-qPCR. Individual results and mean & STD of Ct values are shown.
In conclusion, Vectormune ND is a strong tool to break the uncontrolled transmission of Newcastle disease virus among chickens in a house, in between houses, and ultimately among farms in a densely populated poultry area. Hence, Vectormune ND helps to prevent and control Newcastle disease outbreaks in the poultry industry and protects the performance of the birds. This way, Ceva Animal Health provides more evidence towards supporting its customers worldwide to achieve their targets.
* Tatár-Kis T, Fischer EAJ, Cazaban C, Walkó-Kovács E, Homonnay ZG, Velkers FC, Palya V, Stegeman JA. A Herpesvirus of Turkey-Based Vector Vaccine Reduces Transmission of Newcastle Disease Virus in Commercial Broiler Chickens with Maternally Derived Antibodies. Vaccines (Basel). 2020 Oct 16;8(4):614. doi: 10.3390/vaccines8040614. PMID: 33081359; PMCID: PMC7720113.
Ceva Santé Animale (Ceva) is the 5th global animal health company, led by experienced veterinarians, whose mission is to provide innovative health solutions for all animals to ensure the highest level of care and well-being. Our portfolio includes preventive medicine such as vaccines, pharmaceutical and animal welfare products for farm and companion animals, as well as equipment and services to provide the best experience for our customers. With 6,500 employees located in 47 countries, Ceva strives daily to bring to life its vision as a OneHealth company: “Together, beyond animal health”. 2022 turnover: €1.53 billion. Use the links below to learn more about Ceva.
Ceva Santé Animale (Ceva) is the 5th global animal health company, led by experienced veterinarians, whose mission is to provide innovative health solutions for all animals to ensure the highest level of care and well-being. Our portfolio includes preventive medicine such as vaccines, pharmaceutical and animal welfare products for farm and companion animals, as well as equipment and services to provide the best experience for our customers. With 6,500 employees located in 47 countries, Ceva strives daily to bring to life its vision as a OneHealth company: “Together, beyond animal health”. 2022 turnover: €1.53 billion. Use the links below to learn more about Ceva.
Notifications
Your Privacy Matters
It's your legal right to choose which information a website may store and have access to. With your permission, we and our third-party partners (24) store and/or access information on a device, such as unique identifiers in cookies and browsing data to collect and process personal data.
We and our partners do the following data processing:
Store and/or access information on a device, Advertising based on limited data and advertising measurement, Personalised content, content measurement, audience research, and services development
If you accept any or all of these, you will have agreed to this website's use of cookies for these purposes. You may also choose to refuse consent, but certain personalized features of the site won't be available to you.